Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)
The primary objective of this trial is to assess the presence of resistance to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective of this study is to examine clinicians? use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen. Ideally resistance testing will help clinicians identify active/sensitive ARVs needed to construct a rescue HAART regimen.
|Official Title:||Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)|
- The primary endpoint is the level of sensitivity of a patient?s HIV 1 isolate to tipranavir. Co primary endpoints are the levels of sensitivity of a patient?s HIV 1 isolate to other marketed ARVs (PIs, NRTIs, and NNRTIs).
- a) Protease inhibitor(s) identified by the clinician prior to resistance testing to which a patient?s HIV 1 virus is thought to be susceptible. b) PI that was discontinued or initiated after receiving resistance testing results.
|Estimated Study Completion Date:||January 2008|
Show 36 Study Locations
|Study Chair:||Boehringer Ingelheim Study Coordinator||B.I. Pharmaceuticals,Inc./Ridgefield|